Advertisement

Topics

Latest "Puretech" News Stories

14:53 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "Puretech" found in our extensive news archives from over 250 global news sources.

More Information about Puretech on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Puretech for you to read. Along with our medical data and news we also list Puretech Clinical Trials, which are updated daily. BioPortfolio also has a large database of Puretech Companies for you to search.

Showing "Puretech" News Articles 1–25 of 62

Relevant

Roche Links with PureTech on Exosomes

Swiss pharmaceutical giant Roche has signed up to a multi-year collaboration with PureTech Health, a US clinical stage biopharma focused on the brain-immune-gut axis. The partners will advance PureTech’s milk-derived exosome platform technology for the oral administration of Roche’s antisense oligonucleotide platform.


PureTech’s Milk Exosome-Based Technology Draws R&D Pact With Roche

PureTech's milk-derived exosome platform will be used by Roche to generate numerous novel antisense oligonucleotides, potentially earning PureTech more than...   

Got Milk? Roche to Apply PureTech Exosomes Platform in $1B+ Collaboration

Roche will work to enable oral administration of its antisense oligonucleotide platform using PureTech Health’s milk-derived exosome technology, through a collaboration that PureTech said today could generate for it more than $1 billion. Under the multi-year collaboration, Roche will study applying PureTech’s milk exosomes tech, which is designed to facilitate oral delivery of macromolecul...


PureTech Health and Roche Sign Collaboration Deal Worth $1 Billion-Plus

Boston-based PureTech Health inked a multi-year collaboration deal with Swiss-based Roche to advance PureTech’s milk-derived exosome platform technology for oral dosing of Roche’s antisense oligonucleotide platform.

Roche and PureTech to develop oral antisense oligonucleotides

Roche has signed a multi-year partnership with US-based biopharmaceutical company PureTech Health for the development of its oral antisense oligonucleotide...Read More... The post Roche and PureTech to develop oral antisense oligonucleotides appeared first on Pharmaceutical Technology.

Roche, PureTech partner to develop exosome platform for oral drug delivery

PureTech Health and Roche Holding agreed to work together to develop PureTech's exosome platform for oral delivery of Roche's -More- 

PureTech Health surges as it hooks up with Swiss drugs giant Roche

PureTech Health has been advancing internal R&D projects that focus on the brain-immune-gut axis, with an emphasis on lymphatics and immune cell trafficking to modulate immunity in a tissue-specific manner.

PureTech affiliate Karuna advances schizophrenia candidate

Karuna Pharmaceuticals, an affiliate of UK biopharma PureTech Health, has kicked off a Phase II study of KarXT, which is being developed for the treatment of psychosis in schizophrenia.

PureTech lifted by news of Roche deal

Shares in UK-based clinical-stage biopharm PureTech Health have been given a boost by news that Roche has signed up to advance its exosome platform technology in a deal potentially worth more than $1 billion.

PureTech Health Announces Collaboration with Roche to Advance Technology for Oral ...

PureTech Health to receive up to $36 million in upfront payments, research support, and early preclinical milestones and is eligible to potentially receive over $1 billion in development milestones Read more...

PureTech signs potential $1bn exosome deal with Roche

US biotech PureTech Health has signed a potential billion-dollar deal with Roche based around its exosome technology that allows for oral administration of complex payloads – in this case antisense oligonucleotides developed by the Swiss pharma. P...

PureTech to research Alzheimer's drugs based on 'brain drain' theory

US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain. This revolutionary approach is based on the work of Dr Jonathan Kipnis, Ha...

PureTech Health’s Karuna Snags $42M Series A for Schizophrenia Drug

With $42 million in new investment, Karuna Pharmaceuticals, a PureTech Health company based in Boston, now has the funds to test in a Phase 2 clinical trial a drug for a disease where many have previously failed: schizophrenia. Karuna’s lead candidate, KarXT, is a combination of two compounds: xanomeline, licensed from Eli Lilly (NYSE: LLY), […]

PureTech to use milk-derived exosomes to deliver Roche’s antisense therapies

In a multi-year deal, PureTech Health PLC will use its milk-derived exosome platform to develop oral delivery formulations of...

Wellcome Trust awards $8bn cash injection to trial schizophrenia drug

The Wellcome Trust has awarded $8 million to PureTech’s Karuna to take its schizophrenia drug into mid-stage trials. Karuna, which is an affiliate of PureTech Health, was granted the funding towards the drug KarXT (Karuna-Xanomeline-Trospium), for...

Wellcome Trust awards $8m cash injection to trial schizophrenia drug

The Wellcome Trust has awarded $8 million to PureTech’s Karuna to take its schizophrenia drug into mid-stage trials. Karuna, which is an affiliate of PureTech Health, was granted the funding towards the drug KarXT (Karuna-Xanomeline-Trospium), for...

PureTech’s Vor secures US patent for compositions and methods to treat hematologic malignancies

This foundational patent is the first of its kind in the immuno-oncology field and it broadly covers compositions and therapeutic methods related to using novel modified HSCs to The post PureTech’s Vor secures US patent for compositions and methods to treat hematologic malignancies appeared first on Pharmaceutical Business review.

ReNeuron Group (RENE) - Exosomes rise further

Edison Investment Research - Pharmaceutical & healthcare - ReNeuron Group: ReNeuron’s capital markets day highlighted the potential for the company’s exosome nanomedicine platform to be a source of both product and licensing revenues. This morning’s announcement of a collaboration between PureTech Health and Roche on PureTech’s milk-derived exosome platform highlights the a...

PureTech s Karuna appoints CEO

PureTech, Roche to use exosomes for oral drug delivery

PureTech Founder Steinberg departs for Longwood Fund

PureTech’s Vedanta Biosciences adds Susan Dillon to Board of Directors

PureTech Health to Present at Jefferies 2018 London Healthcare Conference

PureTech Health plc (LSE: PRTC) (“PureTech Health”), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) Axis, today announced that Joep Muijrers, Ph.D., Chief Financial Officer at PureTech Health, will present at the Jefferies 2018 Global Healthcare Conference in London on Thursday, November ...

After many wonderful years at PureTech I am making a transition! Starting September 10 I'll be joining the team at Longwood Fund. I look back with fondness and forward with excitement.

After many wonderful years at PureTech I am making a transition! Starting September 10 I'll be joining the team at Longwood Fund. I look back with fondness and forward with excitement.

Karuna completes $42 million financing round

Participants include ARCH Venture Partners, Wellcome Trust, PureTech Health, Steven Paul MD, and other undisclosed investors


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks